Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FKTN antisense RNA 1 (FKTN-AS1) is a long non-coding RNA transcribed from the antisense strand of the FKTN genomic locus. There is currently no documented biological function, disease association, or therapeutic implication for FKTN-AS1 itself. Drug discovery, therapeutic intervention, and disease mechanism research in the context of Fukuyama congenital muscular dystrophy focus on the FKTN coding gene and its mRNA, particularly via antisense oligonucleotide-mediated exon skipping and splicing modulation; these strategies do not act on FKTN-AS1[1][2][4][6][8]. The FKTN gene encodes ribitol-phosphate transferase, which glycosylates α-dystroglycan, a critical process disrupted in disease, but FKTN-AS1 is not implicated in these pathways in current scientific literature[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FKTN antisense RNA 1 (FKTN-AS1).